Replies to post #115526 on NanoViricides Inc. (NNVC)

[changes_iv]

Red flag: Insiders aren't buying stocks

The stock market is having a terrific week. Momentum is giddy, except for this: the best informed people aren't buying stocks.

Smart investors keep an eye on what the so-called "insiders" are doing -- the CEOs, directors and company founders.

Typically, when the stock market tanks like it did in late August and September, top management will jump at the opportunity to buy cheap stock. It's the ultimate sign of confidence they believe better days are ahead.

But that's not what's happening.

"I've been very surprised," says David Santschi, CEO of TrimTabs Investment Research. "We were looking for a big pick up in insider buying. We didn't see it."

Enthusiasm from insiders has evaporated as the market dropped. It's a cautionary sign.
.
.
.
http://money.cnn.com/2015/10/09/investing/insiders-are-not-buying-stocks/index.html

Enter Dr. Milton Boniuk, an independent director/insider, an astute and highly successful businessman and entrepreneur, in addition to being an accomplished eye surgeon, educator, and administrator...

NanoViricides Reports that its Director, Milton Boniuk, MD, Has Invested a Total of $7M in the Company this Year
By Business Wire |
September 17, 2013

NanoViricides Reports that its Director, Milton Boniuk, MD, Has Invested a Total of $7M in the Company this Year

WEST HAVEN, Conn.--(BUSINESS WIRE)-- NanoViricides, Inc. (OTC BB:NNVCD) (the "Company") reported today that Milton Boniuk, MD, the Caroline F. Elles Chair Professor of Ophthalmology at Baylor College of Medicine, and a Director of the Company has invested a total of $7 Million in the Company during the 2013 calendar year. Dr. Boniuk was the single largest investor with $3 Million in the recently concluded registered direct offering. Previously, he had invested $4 Million in the Company’s convertible debenture financing concluded in February, 2013. Professor Boniuk has also invested in the Company in earlier rounds of financing. He made these investments both personally as well as from his charitable foundation and other interests. Professor Boniuk joined the Company’s Board as an independent director in May, 2013, at the request of the Company’s executives. He says that his confidence in the Company has only continued to grow as he sees the Company’s management and execution now from a closer perspective.
.
.
.

www.fool.com/investing/businesswire/2013/09/17/nanoviricides-reports-that-its-director-milton-bon.aspx

Lately, Dr, Milton Boniuk has been buying with great frequency and confidence!
http://ih.advfn.com/p.php?pid=nmona&article=68529003
http://ih.advfn.com/p.php?pid=nmona&article=68325023
http://ih.advfn.com/p.php?pid=nmona&article=68296181

NanoViricides, Inc. (2015) is advancing the FluCide(TM) candidate.

"There are many reasons an insider will sell a stock, but only one reason why insiders buy: They think the stock is undervalued and will eventually go up." ~ Peter Lynch

About commissioning and validation of the new, state of the art, Pilot Plant in Shelton, CT:

Jan. 7, 2015...All of the infrastructure systems needed for production of the nanoviricides® drug candidates are now operational at the new facility, and have either been validated by outside experts, or are in the process of such validation.

http://www.prnewswire.com/news-releases/nanoviricides-inc-completes-purchase-of-cgmp-compliant-pilot-production-facility-300017051.html

April 27, 2015...In another news, the Company reports that the process of commissioning of its new facility in Shelton is on course. Our Bio-Analysis Group has already moved operations to the new facility. Large Scale Chemistry Group is completing the necessary modifications to the facility to enable large scale production processes. Various laboratory instruments are being installed by vendors under warranty programs for installation qualification and operational qualification.

http://www.nanoviricides.com/press%20releases/2015/NanoViricides%20Discusses%20the%20Strong%20Effectiveness%20of%20Its%20Anti-Herpes%20Drug%20Candidates%20in%20a%20Lethal%20Animal%20Model%20of%20Dermal%20Herpes%20Infection.html

Commissioning and validation of a new pharmaceutical facility should be considered the optimal goal, as the ROI is not realized until the facility can make product. Budgets and timelines usually become the target focus through a majority of traditional construction projects, sometimes leaving the commissioning and validation of the facility as the final area of focus [3].
www.pharmamanufacturing.com/articles/2004/41/

It is important to note:

1) NanoViricides, Inc. began the process of commissioning the new state-of-the-art, multi-kilogram Pilot Plant in Shelton, CT, to produce FluCide(TM)/GLP, sometime in Jan 2015

2) On Mar 31, 2015 - We are now progressing to a 1kg scale-up of FluCide(TM), and enabling in-process control instrumentation--- CMC studies to enable further scale-up from the current multi-100g scale of production to kg-scale production. CMC stands for "Chemistry, Manufacture, and Controls," and relates to being able to make the drug substance and the drug product in a reproducible fashion, batch after batch.

-We are now making the FluCide(TM) material for final/Phase III of Safety/Toxicology Studies in large animals!

June 1, 2015, 9:47 PM

FluCide

Phase I and II of tox successfully completed

Making material for last Phase in large animals

...

Eugene Seymour MD MPH
Chief Executive Officer
NanoViricides, Inc
[e-mail]
www.nanoviricides.com
310-486-5677
"NNVC" on the New York Stock Exchange

=============================================

About an excerpt from one of Patrick Cox's letter and NanoViricides, Inc....

The more transformational a technology is, the easier it is to get people doubting it. Take, for example, NanoViricides (OTCBB: NNVC). This company's remarkable technology combines nano-sized polymer structures with biological ligands -- nanoviricides. The ligands "signal" to the target viruses that they are inside human cells. The viruses attack these nanoviricides and are, in turn, dismantled and harmlessly removed.

I know this sounds like science fiction.

In fact, the company has proven the technology over and over in conjunction with some of the world's most important scientists. It's real. It works, and it will revolutionize the way medical science deals with a broad range of viruses. Viruses, incidentally, are only now beginning to be truly understood. It appears, in fact, that they play roles in conditions we never suspected, ranging from obesity to chronic fatigue syndrome. So NanoViricides' future is vast.

Nevertheless, there is a minor industry based on convincing investors that NanoViricides is some sort of hoax. For a long time, if you did a Google search on the company name, the top paid search results were screaming claims that the company was a scam. If you searched my name, it often returned accusation that I was part of the NanoViricides scam.

I wish, by the way, that I did own part of NanoViricides. I am prohibited by my arrangement with Agora Financial.

Dr. Eugene Seymour told me that he had tried to contact Google about putting an end to this slander, but could never get a response. Google's informal corporate slogan, by the way, is "Don't be evil."

Anyway, there are several reasons that people might attack a company in this manner. Some are probably simply trying to sell a report about NanoViricides, or at least get credit card information from people foolish enough to fall for the trick.

Sometimes, however, these tactics are part of a broader short attack. Many of you know, in fact, that these short attacks are taking place because you have been offered money to "rent" your shares. I hear about it constantly, and this does not happen to just NanoViricides. The last time I reported it, Pro-Pharmaceuticals was being targeted.

In general, the greater the company's potential, the more attractive it is to short attackers. If a company has generated a lot of "buzz," it is likely that a lot of "traders" have decided to buy shares. These people often know nothing about the company's management, technology or market potential. They're just surfing trends.

As a result, groups that specialize in short attacks can manipulate them. These groups are expert at spreading rumors. They seem to have people planted on the boards who can say just the right thing at just the right time to trigger a stampede.

When I lived in Silicon Valley, I knew quite well the man who was then Steve Jobs' CFO. He frequently described his job in terms of warfare. I was skeptical at first, but he convinced me that a group of people were waging war against him and his company. If he didn't fight back, they would succeed.

Why would anybody attack a company run by Steve Jobs? They did so because sophisticated traders, as you know, can make money by driving a stock price down. In the age of the Internet, with the means to reach millions of investors, this has become a serious problem. Normally, I try to ignore these attacks because they usually don't hurt the companies they attack. They hurt the investors who sell their stock at low prices. ~ Patrick Cox, Jan 11, 2011

Excerpt from NanoViricides, Inc, CEO letter to shareholders (2014)

Recent “Bear” Attack

As many of you know, a malicious and possibly criminal attack on our common stock was carried out on February 11, 2014, through the publication of a false and misleading article on Seeking Alpha. The intent of the article was to dramatically drive down our stock price. The article resulted in a highly increased daily trading volume of eight million shares, approximately 20 times our daily average. The information we have gathered suggests that this was an organized attack using false and inaccurate information designed to benefit short sellers in the stock. We have reported this conduct to the regulatory authorities and have retained legal counsel to investigate both the website that hosted this article and the anonymous blogger who authored it.

www.nanoviricides.com/2014-ceo-letter.pdf